Woofun AI reports that Jiuan Medical has reached the daily price limit for four consecutive trading sessions. The company projects its first-half net profit attributable to the parent company to range between 2.8 billion yuan and 3.4 billion yuan, representing a year-on-year increase of 204.29% to 269.50%. This growth is primarily driven by valuation increases in its scientific and technological innovation investments. Through Tianjin Shixiang, Jiuan Hong Kong indirectly invested 750 million yuan in DeepSeek, resulting in an equity penetration of approximately 0.21% with no operational involvement.

Additionally, the firm invested $10 million and $20 million in Moon's Dark Side in August 2023 and March 2024, respectively, and contributed 100 million yuan to Jieyue Xingchen via the Begonia-Sunrise Fund in June 2026. These holdings are classified as financial investments with low shareholding ratios. Jiuan Medical subscribed 2.48 billion yuan to a sci-tech innovation mother fund, creating a sub-fund pool nearing 13.7 billion yuan after leverage. The company also holds six direct investment projects totaling 330 million yuan. While medical equipment remains its core business, profits are increasingly influenced by primary market valuations. The firm warns that these investments carry risks including long payback periods, low liquidity, and potential valuation declines.